Table 4 Meta-analysis of the subgroup including studies performed in NSCLC treated by surgery, with their characteristics
Group of NSCLC: surgical stages ( n =7) | |||||||
|---|---|---|---|---|---|---|---|
Study | Method | Threshold | QS (%) | N Pts | Bcl-2+ (%) | HR | 95% CI |
Fontanini et al (1995, 1996) | IHC-clone 124 | >1 | 45 | 89 | 66 | 0.28 | 0.14–0.55 |
Ghosh et al (1999) | IHC-clone 124 | >50 | 41 | 134 | 31 | 0.60 | 0.40–0.90 |
Higashiyama et al (1997) | IHC-clone 124 | >10 | 52 | 174 | 21 | 0.47 | 0.20–1.14 |
Huang et al (1999) | IHC-clone 124 | >50 | 70 | 203 | 39 | 0.46 | 0.26–0.82 |
Ishida et al (1997) | IHC-clone 124 | >10 | 64 | 114 | 38 | 0.23 | 0.06–0.86 |
Kim et al (1998) | IHC-clone 124 | NM | 79 | NM | NM | 2.50 | 0.90–7.1 |
Laudanski et al (1999) | IHC-clone 124 | NM | 68 | 84 | 46 | 0.41 | 0.21–0.79 |
Overall (fixed-effects model) | 798 | 37 | 0.50 | 0.39–0.65 | |||
Overall (random-effects model) | 0.50 | 0.33–0.77 | |||||
χ2 statistic for heterogeneity=14.98, 6 df, P=0.02 | |||||||
